| D007538 |
Isoniazid |
Antibacterial agent used primarily as a tuberculostatic. It remains the treatment of choice for tuberculosis. |
Isonicotinic Acid Hydrazide,Ftivazide,Isonex,Isonicotinic Acid Vanillylidenehydrazide,Phthivazid,Phthivazide,Tubazide,Acid Vanillylidenehydrazide, Isonicotinic,Hydrazide, Isonicotinic Acid,Vanillylidenehydrazide, Isonicotinic Acid |
|
| D008297 |
Male |
|
Males |
|
| D010131 |
Aminosalicylic Acid |
An antitubercular agent often administered in association with ISONIAZID. The sodium salt of the drug is better tolerated than the free acid. |
4-Aminosalicylic Acid,p-Aminosalicylic Acid,para-Aminosalicylic Acid,Alumino-4-Aminosalicylic Acid,Pamisyl,Rezipas,p-Aminosalicylic Acid Monolithium Salt,p-Aminosalicylic Acid Monopotassium Salt,p-Aminosalicylic Acid Monosodium Salt,p-Aminosalicylic Acid, Aluminum (2:1) Salt,p-Aminosalicylic Acid, Calcium (2:1) Salt,p-Aminosalicylic Acid, Monosodium Salt, Dihydrate,4 Aminosalicylic Acid,Acid, Aminosalicylic,Alumino 4 Aminosalicylic Acid,p Aminosalicylic Acid,p Aminosalicylic Acid Monolithium Salt,p Aminosalicylic Acid Monopotassium Salt,p Aminosalicylic Acid Monosodium Salt,para Aminosalicylic Acid |
|
| D002986 |
Clinical Trials as Topic |
Works about pre-planned studies of the safety, efficacy, or optimum dosage schedule (if appropriate) of one or more diagnostic, therapeutic, or prophylactic drugs, devices, or techniques selected according to predetermined criteria of eligibility and observed for predefined evidence of favorable and unfavorable effects. This concept includes clinical trials conducted both in the U.S. and in other countries. |
Clinical Trial as Topic |
|
| D004341 |
Drug Evaluation |
Any process by which toxicity, metabolism, absorption, elimination, preferred route of administration, safe dosage range, etc., for a drug or group of drugs is determined through clinical assessment in humans or veterinary animals. |
Evaluation Studies, Drug,Drug Evaluation Studies,Drug Evaluation Study,Drug Evaluations,Evaluation Study, Drug,Evaluation, Drug,Evaluations, Drug,Studies, Drug Evaluation,Study, Drug Evaluation |
|
| D004359 |
Drug Therapy, Combination |
Therapy with two or more separate preparations given for a combined effect. |
Combination Chemotherapy,Polychemotherapy,Chemotherapy, Combination,Combination Drug Therapy,Drug Polytherapy,Therapy, Combination Drug,Chemotherapies, Combination,Combination Chemotherapies,Combination Drug Therapies,Drug Polytherapies,Drug Therapies, Combination,Polychemotherapies,Polytherapies, Drug,Polytherapy, Drug,Therapies, Combination Drug |
|
| D005260 |
Female |
|
Females |
|
| D006801 |
Humans |
Members of the species Homo sapiens. |
Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man |
|
| D000328 |
Adult |
A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. |
Adults |
|
| D013307 |
Streptomycin |
An antibiotic produced by the soil actinomycete Streptomyces griseus. It acts by inhibiting the initiation and elongation processes during protein synthesis. |
Estreptomicina CEPA,Estreptomicina Clariana,Estreptomicina Normon,Strepto-Fatol,Strepto-Hefa,Streptomycin GrĂ¼nenthal,Streptomycin Sulfate,Streptomycin Sulfate (2:3) Salt,Streptomycin Sulphate,Streptomycine Panpharma,Strepto Fatol,Strepto Hefa |
|